- Home
- CAVA vs MIRM Comparison
CAVA vs MIRM Comparison
Compare CAVA & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CAVA | MIRM |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 7.2B |
| IPO Year | 2023 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CAVA | MIRM |
|---|---|---|
| Price | $61.77 | $96.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 28 | 14 |
| Target Price | $81.25 | ★ $153.43 |
| AVG Volume (30 Days) | ★ 2.7M | 657.7K |
| Earning Date | 11-04-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | ★ 0.39 | N/A |
| Revenue | ★ $1,179,664,000.00 | $19,138,000.00 |
| Revenue This Year | $27.36 | $37.56 |
| Revenue Next Year | $20.82 | $16.25 |
| P/E Ratio | $154.31 | ★ N/A |
| Revenue Growth | ★ 22.41 | N/A |
| 52 Week Low | $43.41 | $63.23 |
| 52 Week High | $98.79 | $130.00 |
Technical Indicators
Market Signals| Indicator | CAVA | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 59.91 | 53.04 |
| Support Level | $60.12 | $78.07 |
| Resistance Level | $74.38 | $88.31 |
| Average True Range (ATR) | 2.91 | 3.00 |
| MACD | 0.94 | 0.99 |
| Stochastic Oscillator | 79.08 | 83.04 |
Price Performance
Historical ComparisonAbout CAVA CAVA Group Inc.
Cava is an emerging fast-casual restaurant chain with $1.2 billion in sales across 439 US company-owned units in 2025. The firm derives most of its revenue from the sale of Mediterranean- and Greek-inspired customizable bowls, salads, pita wraps, and beverages, using an assembly-line format. Cava centrally prepares and manufactures the sauces and dips served in its restaurants and sold in grocery stores. All of Cava's revenue is in the US, with the majority of its footprint in the Southeast and Southwest.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.